Acta Chim. Sinica ›› 2019, Vol. 77 ›› Issue (3): 287-292.DOI: 10.6023/A18110472 Previous Articles    

Article

纳米孔技术对PD-1抗原抗体结合检测的实验研究

傅方舟a,b, 张志诚a,b, 孙倩怡a,b, 徐冰a,b, 沙菁㛃a,b   

  1. a 东南大学 江苏省微纳生物医疗器械设计与制造重点实验室 南京 211189;
    b 东南大学机械工程学院 南京 211189
  • 收稿日期:2018-11-22 出版日期:2019-03-15 发布日期:2019-01-18
  • 通讯作者: 沙菁? E-mail:major212@seu.edu.cn
  • 基金资助:

    项目受国家自然科学基金(Nos.51675101,51435003,51375092)和江苏省研究生科研创新计划项目(SJCX18_0019)资助.

Label-free Detection of PD-1 Antibody and Antigen Immunoreaction Using Nano-Sensors

Fu Fangzhoua,b, Zhang Zhichenga,b, Sun Qianyia,b, Xu Binga,b, Sha Jingjiea,b   

  1. a Jiangsu Key Laboratory for Design and Manufacture of Micro-Nano Biomedical Instruments, Southeast University, Nanjing 211189;
    b School of Mechanical Engineering, Southeast University, Nanjing 211189
  • Received:2018-11-22 Online:2019-03-15 Published:2019-01-18
  • Supported by:

    Project supported by the National Natural Science Foundation of China (Nos. 51675101, 51435003, 51375092) and the Postgraduate Research & Practice In-novation Program of Jiangsu Province (SJCX18_0019).

Immunotherapy for cancer is a method to treat cancer by using the body's own immune system. Programmed death receptor 1 (PD-1) is one of the checkpoints in the immunotherapy. The signal pathway PD-1 (programmed death receptor 1)/PD-L1 (ligand of PD-1) is closely related to the immune escape of the cancer cells. The inhibitor drugs for PD-1 checkpoint, essentially the monoclonal antibodies of PD-1 or PD-L1 which is essentially the immune checkpoints inhibitors could block the PD-1/PD-L1 pathway and reactivate T-cells to kill cancer cells, and as a result, the immunotherapy for cancer is realized. In order to study the binding process of PD-1 drugs and PD-1 antigen in vivo, in this work, solid-state nanopore as a single molecule method is used to detect the binding of PD-1 antibody and antigen. The PD-1 antibody as well as antigen is driven though the same nanopore under the same experimental condition by the external electric field. Since the antibody's block is about 0.01297 while the antigen's block is 0.00404, the PD-1 antibody is distinguished with the PD-1 antigen according to the theoretical formula. Driving the PD-1 antigen though the nanopore modified by PD-1 antibody (a series of experiments are conducted for characterization) under the same temperature and buffer concentration, the antibody-antigen complexes are detected and distinguished with PD-1 protein and its antibody through the relative current drop analysis and the current drop achieved before. The results suggest that the antibody and antigen have a specific binding (the smaller peak represents the free PD-1 antibody and antigen) and the binding process can be detected by nano-sensors. So the nanopore is able to distinguish the antibody, the antigen and the complexes without any labling. And in the future, the nanopore technology may be a rapid and label-free way for patients and doctors to evaluate the drugs' efficiency.

Key words: nanopore, programmed death receptor 1 (PD-1), antibody, antigen, label-free